| Chronic Lymphocytic Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| Antineoplastic Drug |
0 |
0.97 |
| Monoclonal Antibody |
0 |
0.69 |
| Leukemia |
0 |
0.48 |
| Tyrosine Kinase Inhibitor |
0 |
0.42 |
| Cancer |
0 |
0.4 |
| COVID-19 |
0 |
0.4 |
| Targeted Cancer Therapy |
0 |
0.98 |
| Tyrosine Kinase |
0 |
0.3 |
| Myelodysplastic Syndrome |
0 |
0.25 |
| Acute Leukemia |
0 |
0.22 |
| Acute Myeloblastic Leukemia |
0 |
0.21 |
| Patient Safety |
0 |
0.21 |
| Adverse Effects |
0 |
0.2 |
| Hypertension |
0 |
0.18 |
| Blood |
0 |
0.1 |
| Cardiovascular disease |
0 |
0.1 |
| Cardiovascular Risk Management |
0 |
0.1 |
| Chemotherapy |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Leukopenia |
0 |
0.1 |
| Ohio |
0 |
0.1 |
| Sudden Cardiac Death |
0 |
0.1 |
| Texas |
0 |
0.1 |
| UK Site Content |
0 |
0.1 |